← All trials
NCT04384367
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 28, 2021
- Primary completion
- Jul 30, 2022
- Completion date
- Oct 30, 2022
- First posted
- May 12, 2020
- Last posted
- May 13, 2020
- Enrollment
- 1524
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Eurofarma Laboratorios S.A.Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.